Scholarlink

Summary <p>Equine piroplasmosisis a tick-borne haemoprotozoan disease of equine population (horses, mules, donkeys and zebras) caused either by T. equi or B. caballi. Clinically it is characterized by pyrexia, hemolytic anemia and jaundice. Intravascular hemolysis and development of oxidative stress are key pathological alterations. Disease is endemic in almost all part of world (tropical, subtropical, temperate regions) except some courtiers which are EP free like US, UK, Northern Europe, Iceland and New Zealand. These countries follow strict quarantine measures and T. equi infection leads to development of seropositive horse lifetime while B. caballi infection can lead to carrier state for next few years. Significant economic loss occurs in the form of treatment cost, loss of foetus, reduced performance, mortality and restriction in animal’s movement. Diagnosis can be made on the basis of typical clinical signs, optical microscopy, serology and molecular diagnosis. Currently cELISA is an OIE recommended test for international movement of horses in EP free countries. Conventional drug therapy includes use of Imidocarb dipropionate for both T. equi and B. Caballi. Other alternate therapies involve use of oxytetracycline, buparvaquone, amicarbalide and various drug combinations. Since no vaccine is available till now, effective tick control strategies, early diagnosis and treatment of disease, application of advance therapy remains the only way to control EP now days.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Equine piroplasmosis: an emerging tick-borne threat to equine health

  • 期刊论文

  • 发表日期：

    2026年1月5日

查看全文
  • Kapil Kumar Gupta,
  • Neha Gupta,
  • Sanjay Kumar,
  • Mukesh Srivastava,
  • Pradeep Kumar

摘要

Summary

Equine piroplasmosisis a tick-borne haemoprotozoan disease of equine population (horses, mules, donkeys and zebras) caused either by T. equi or B. caballi. Clinically it is characterized by pyrexia, hemolytic anemia and jaundice. Intravascular hemolysis and development of oxidative stress are key pathological alterations. Disease is endemic in almost all part of world (tropical, subtropical, temperate regions) except some courtiers which are EP free like US, UK, Northern Europe, Iceland and New Zealand. These countries follow strict quarantine measures and T. equi infection leads to development of seropositive horse lifetime while B. caballi infection can lead to carrier state for next few years. Significant economic loss occurs in the form of treatment cost, loss of foetus, reduced performance, mortality and restriction in animal’s movement. Diagnosis can be made on the basis of typical clinical signs, optical microscopy, serology and molecular diagnosis. Currently cELISA is an OIE recommended test for international movement of horses in EP free countries. Conventional drug therapy includes use of Imidocarb dipropionate for both T. equi and B. Caballi. Other alternate therapies involve use of oxytetracycline, buparvaquone, amicarbalide and various drug combinations. Since no vaccine is available till now, effective tick control strategies, early diagnosis and treatment of disease, application of advance therapy remains the only way to control EP now days.